Pharma Michel Dutree, former director general of the Dutch association for pharmaceutical innovators, gives a detailed overview of the changes happening in the Dutch pharmaceutical industry, and the Netherlands’ role at the European level as the “laboratory of Europe.” It’s been four years since your last interview with PBR; what do…
Research Arnaud Lagesse, CEO of GML, the largest company in Mauritius and the third largest company in the Indian Ocean, discusses his company’s successful diversification into the life sciences sector, with the creation of GML Life. The history of GML has always been linked to the development of the Mauritian economy.…
Pharma Beurs Van Berlage is an historic conference center in Amsterdam, hosting thousands of participants each year, many of them physicians, scientists, and professionals attending seminars, conferences, and meetings related to groundbreaking developments in medicine. The institution’s managing and commercial director discuss their organization’s suitability for hosting life science conferences. Could you…
Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…
Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…
healthcare Nefarma’s healthcare policy advisor discusses the changes in the Dutch reimbursement system over the previous five years, and the need for greater trust between different healthcare stakeholders to allow effective collaboration and negotiation. How has the pharmaceutical reimbursement system in the Netherlands changed over the last few years? To start…
South Africa The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa has been chosen as the company´s hub for Africa, and how they have consistently been selected as one the best…
Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…
Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…
universal healthcare Berlin Pharmaceutical Industry’s CEO, Amal Naj, explains how he has grown the company, its next regional and medical targets, and his vision for its future. What has led to Berlin Pharmaceutical’s success over the last five years? In 2010, the market was going through a major transition due to the progressive…
government PharmaBoardroom met the Secretary General of the Thai FDA and the Senior Expert on Pharmaceutical Standards at the FDA. They explained the FDA’s role in Thailand’s pharma market, what the organization is doing for Thai copyright rights, how it is promoting international investment and integration within the ASEAN Economic Community. Please introduce…
Puerto Rico Puerto Rico’s healthcare insurance market is the first in Latin America in terms of penetration and sixth in terms of premium volume. Ángela Weyne, Insurance Commissioner of Puerto Rico, discusses how recent amendments to the Affordable Care Act (ACA) have been implemented locally, how she is spurring healthy competition among…
See our Cookie Privacy Policy Here